UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 148

Sortiert nach

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Journal of clinical oncology, 2021-12, Vol.39 (35), p.3959-3977

2021

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2585-2592

2012

Link zum Volltext

Verfügbarkeit prüfen

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Journal of clinical oncology, 2016-09, Vol.34 (25), p.3069-3103

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1124-1130

2010

Link zum Volltext

Verfügbarkeit prüfen

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (8), p.1301-1307

2010

Link zum Volltext

Verfügbarkeit prüfen

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Journal of clinical oncology, 2010-08, Vol.28 (23), p.3784-3796

2010

Link zum Volltext

Verfügbarkeit prüfen

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

Journal of clinical oncology, 2011-02, Vol.29 (6), p.632-638

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Link zum Volltext

Verfügbarkeit prüfen

Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease

Journal of clinical oncology, 2008-02, Vol.26 (5), p.814-819

2008

Link zum Volltext

Verfügbarkeit prüfen

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3328-3330

2011

Link zum Volltext

Verfügbarkeit prüfen

American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7703-7720

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1993-1999

2008

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

Cancer, 2007-09, Vol.110 (5), p.965-972

2007

Link zum Volltext

Verfügbarkeit prüfen

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply

The New England journal of medicine, 2021-03, Vol.384 (12), p.1176-1177

Burstein, Harold J

2021

Link zum Volltext

Verfügbarkeit prüfen

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Cancer, 2003-06, Vol.97 (12), p.2972-2977

2003

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

Clinical cancer research, 2007-02, Vol.13 (4), p.1198-1207

2007

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Journal of clinical oncology, 2019-02, Vol.37 (5), p.423-438

2019

Link zum Volltext

Verfügbarkeit prüfen

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

Clinical cancer research, 2008-12, Vol.14 (23), p.7871-7877

2008

Link zum Volltext

Verfügbarkeit prüfen

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Journal of clinical oncology, 2023-06, Vol.41 (18), p.3423-3425

2023

Link zum Volltext

Verfügbarkeit prüfen

Quality of Non–Breast Cancer Health Maintenance Among Elderly Breast Cancer Survivors

Journal of clinical oncology, 2003-04, Vol.21 (8), p.1447-1451

2003

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Endocrine Therapy for Women With Hormone Receptor―Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Journal of clinical oncology, 2014-07, Vol.32 (21), p.2255-2269

2014

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations

JAMA : the journal of the American Medical Association, 2021-01, Vol.325 (1), p.36

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 148

Suche als RSS-Feed

Aktive Filter

ThemaChemotherapy

KollektionNUS Single-Journal Subscriptions

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(141)

Publikationsform

Sprache

Englisch
(148)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Humans
(89)
Life Sciences & Biomedicine
(88)
Science & Technology
(88)
Female
(79)
Oncology
(73)
Breast Neoplasms - Drug Therapy
(61)
Biological And Medical Sciences
(47)
Medical Sciences
(45)
Tumors
(43)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(35)
Breast Neoplasms - Pathology
(30)
Gynecology. Andrology. Obstetrics
(29)
Mammary Gland Diseases
(29)
Middle Aged
(29)
Chemotherapy, Adjuvant
(24)
Aged
(23)
Breast Cancer
(23)
Antineoplastic Agents - Therapeutic Use
(21)
Adult
(20)
Disease-Free Survival
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Quality of Non–Breast Cancer Health Maintenance Among Elderly Breast Cancer Survivors

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Adjuvant Endocrine Therapy for Women With Hormone Receptor―Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations

Aktive Filter

Suchergebnisse filtern